Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBITDA (2016 - 2025)

Veracyte (VCYT) has disclosed EBITDA for 14 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 790.9% to $37.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.8 million through Dec 2025, up 257.93% year-over-year, with the annual reading at $57.8 million for FY2025, 257.93% up from the prior year.
  • EBITDA hit $37.2 million in Q4 2025 for Veracyte, up from $22.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $37.2 million in Q4 2025 to a low of -$41.9 million in Q1 2021.
  • Historically, EBITDA has averaged -$6.6 million across 5 years, with a median of -$8.5 million in 2021.
  • Biggest five-year swings in EBITDA: crashed 555.11% in 2023 and later surged 790.9% in 2025.
  • Year by year, EBITDA stood at -$12.3 million in 2021, then skyrocketed by 56.05% to -$5.4 million in 2022, then plummeted by 555.11% to -$35.5 million in 2023, then soared by 111.76% to $4.2 million in 2024, then soared by 790.9% to $37.2 million in 2025.
  • Business Quant data shows EBITDA for VCYT at $37.2 million in Q4 2025, $22.9 million in Q3 2025, and -$5.3 million in Q2 2025.